Getting your player ready...
NEW YORK — Abbott Laboratories on Monday said it would pay $6.6 billion for the pharmaceutical business of Belgian chemicals maker Solvay in a move to further expand internationally and add to its product portfolio.
Solvay’s flu vaccine Influvac will give Abbott an entrant in the burgeoning vaccines market, which is dominated by European pharmaceutical giants such as GlaxoSmithKline and Novartis. The Associated Press
